Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma.

Bowen SG, Allison DB, Hensley PJ, Myint ZW

DOI: 10.3389/fonc.2025.1608291
Published: 2025
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2025.1608291,
  title = {Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma.},
  author = {Bowen SG and Allison DB and Hensley PJ and Myint ZW},
  year = {2025},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2025.1608291},
  url = {https://doi.org/10.3389/fonc.2025.1608291}
}

RIS

TY  - JOUR
TI  - Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma.
AU  - Bowen SG
AU  - Allison DB
AU  - Hensley PJ
AU  - Myint ZW
PY  - 2025
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2025.1608291
UR  - https://doi.org/10.3389/fonc.2025.1608291
ER  -

APA

SG, B., DB, A., PJ, H., & ZW, M. (2025). Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1608291

Source records

pubmed · retrieved 2026-09-25T06:30:43.230Z